External validation of the PROGRESS-CTO complication risk scores: Individual patient data pooled analysis of 3 registries
Bahadir Simsek,Peter Tajti,Mauro Carlino,Soledad Ojeda,Manuel Pan,Stephane Rinfret,Evangelia Vemmou,Spyridon Kostantinis,Ilias Nikolakopoulos,Judit Karacsonyi,Joseph A Dens,Pierfrancesco Agostoni,Khaldoon Alaswad,Michael Megaly,Alexandre Avran,James W Choi,Farouc A Jaffer,Darshan Doshi,Dimitri Karmpaliotis,Jaikirshan J Khatri,Paul Knaapen,Alessio La Manna,James C Spratt,Masaki Tanabe,Simon Walsh,Olga C Mastrodemos,Salman Allana,Athanasios Rempakos,Bavana V Rangan,Omer Goktekin,Sevket Gorgulu,Paul Poommipanit,Kathleen E Kearney,William L Lombardi,J Aaron Grantham,Kambis Mashayekhi,Emmanouil S Brilakis,Lorenzo Azzalini
DOI: https://doi.org/10.1016/j.ijcard.2022.12.036
2023-03-15
Abstract:Background: Chronic total occlusion (CTO) percutaneous coronary intervention (PCI) is associated with a considerable risk of complications, and risk stratification is of utmost importance. Aims: To assess the clinical usefulness of the recently developed PROGRESS-CTO (NCT02061436) complication risk scores in an independent cohort. Methods: Individual patient data pooled analysis of 3 registries was performed. Results: Of the 4569 patients who underwent CTO PCI, 102 (2.2%) had major adverse cardiovascular events (MACE). Patients with MACE were older (69 ± 11 vs. 65 ± 10, p < 0.001), more likely to have a history of prior coronary artery bypass graft surgery, and unfavorable angiographic characteristics J-CTO score (2.4 ± 1.2 vs. 2.1 ± 1.3, p = 0.007), including blunt stump (59% vs. 49%, p = 0.047). Technical success was lower in patients with MACE (59% vs. 86%, p < 0.001). The area under the receiver operating characteristic curve of the PROGRESS-CTO complication risk models were as follows: MACE 0.72 (95% confidence interval [CI], 0.67-0.76), mortality 0.73 (95% CI, 0.61-0.85), and pericardiocentesis 0.69 (95% CI, 0.62-0.77) in the validation dataset. The observed complication rates increased with higher PROGRESS-CTO complication scores. The PROGRESS-CTO MACE score showed good calibration in this external cohort, with MACE rates similar to the original study: 0.7% (score 0-1), 1.5% (score 2), 2.2% (score 3), 3.8% (score 4), 4.9% (score 5), 5.8% (score 6-7). Conclusion: Given the good discriminative performance, calibration, and ease of calculation, the PROGRESS-CTO complication scores could help assess the risk of complications in patients undergoing CTO PCI.